Ajinomoto Co., Ltd.

Tomoko Takeda

Hajime Koganei

Seiji Niwa

Akira Takahara

Yukitsugu Ono

Seiji Ohno

Satoshi Iwayama

Shinichi Fujita

Kayo Otani

Takashi Yamamoto

Morikazu Kito

Yuki Kajigaya

Masako Hagihara

Akiko Okajima

Keiko Moki

Hiroshi Yamamoto

Hideki Matsumoto

Manabu Suzuki

Munetaka Tokumasu

Hiroyuki Matsueda

Yoko Masuzawa

Tetsuo Yano

Miho Ono

Masaki Hashimoto

Tomohisa Okutsu

Hideki Suzuki

Chika Nakanishi

Akira Nakajo

The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: wherein, A represents CH&#x2550;CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V&#x2014;W represents C&#x2550;C, etc., n represents 0 to 3, Y1 represents O etc., B represents &#x2014;(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents &#x2014;CO&#x2014;, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group, &#x2014;COR18a, &#x2014;COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

Diarylalkene derivatives and novel diarylalkane derivatives

Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-&#x3b1;. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-&#x3b1; production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

Therapeutic agent for inflammatory bowel disease and TNF-&#x3b1; production inhibitor

The present invention relates to a pharmaceutical composition useful for preventing/treating pain, which comprises combination of gabapentin or pregabalin, or pharmaceutically acceptable salts thereof and N-type calcium channel antagonists or pharmaceutically acceptable salts thereof such as a compound having the following structure. 

Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist

Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels. 

Pyridine compounds useful as N-type calcium channel antagonists

Achiral pyrimidine derivatives and pyridine derivatives of the following formulae or analogs thereof have selective N-type calcium channel antagonistic activity and showed analgesic action when they were taken orally. They are useful as therapeutic agents for pains and various diseases associated with the N-type calcium channels 

Pyrimidine compounds useful as N-type calcium channel antagonists

Compounds having a selective N-type calcium channel antagonistic activity are provided. Dihydropyridine derivatives represented by the following formula: analogs thereof and pharmaceutically acceptable salts thereof have an activity of selectively inhibiting the action of N-type calcium channel, and they are used as therapeutic agents for various diseases relating to N-type calcium channel.

Dihydropyridine derivatives

Dihydropyrimidine derivatives of the following formula or analogs thereof have selective N-type calcium channel antagonistic activity, and they are used as therapeutic agents for various diseases participating in the N-type calcium channels.

Dihydropyrimidine compounds and compositions containing the same

Growing community of inventors

Kawasaki, Japan

Tomoko Takeda